Menopause and Perimenopause Symptoms and Treatment

Key points#

• Perimenopause is the years of hormonal fluctuation before the last period; menopause is confirmed after 12 straight months without one. Both are a normal life stage, not a disease to be cured.
• Hot flashes and night sweats are the most common bothersome symptoms, and they last longer than most people assume. In the SWAN cohort, frequent vasomotor symptoms ran a median of about 7.4 years.
• Hormone therapy is the most effective treatment for bothersome hot flashes and for genitourinary symptoms, and it helps prevent bone loss, per The Menopause Society 2022 position statement.
• The benefit-to-risk balance of hormone therapy shifts with age and timing: it tends to favor treatment for most people under 60 or within 10 years of their final period, without contraindications.
• Real nonhormonal options exist, including certain SSRIs and SNRIs, gabapentin, cognitive behavioral therapy, clinical hypnosis, and fezolinetant.
• Vaginal and urinary symptoms are a distinct problem with distinct fixes, and local low-dose therapy carries a different risk profile than systemic treatment.

Menopause and perimenopause: symptoms and treatment at a glance#

The essentials fit in a paragraph. Perimenopause is the transition of several years when ovarian hormones fluctuate and periods turn irregular; menopause is the single point confirmed after 12 months with no period. The most common symptoms are hot flashes, night sweats, disrupted sleep, and vaginal or urinary changes, and they often last longer than people expect. Treatment for menopause and perimenopause symptoms ranges from hormone therapy, which is the most effective option for bothersome hot flashes, to evidence-backed nonhormonal choices and local therapy for genitourinary symptoms.

The whole menopause transition is defined by one event: the final menstrual period. Everything else is named relative to it, so it helps to take the stages in order.

Perimenopause is the stretch leading up to that final period, often several years long, when the ovaries produce estrogen and progesterone less predictably. Cycles get irregular. They may shorten, then lengthen, then skip. Symptoms such as hot flashes and disrupted sleep frequently start here, while periods are still happening, which surprises people who assume symptoms only arrive after periods stop.

Menopause is a single point in time, confirmed in hindsight after 12 consecutive months with no menstrual period and no other cause. Once that year has passed, a person is postmenopausal. In the United States the average age of menopause is in the early 50s (roughly 51 to 52), with a normal range on either side, according to the National Institute on Aging.

It helps to say plainly what this is and is not. Menopause is a physiologic life stage, not a diagnosis to be cured. The goal of care is not to reverse it but to treat symptoms that bother you and to weigh anything that affects long-term health, such as bone density. This article describes what changes, what is common, and what the evidence says helps, without hype in either direction.

Which symptoms are common, and how long they tend to last#

The symptoms cluster into a few recognizable groups, and no one person gets all of them:

• Vasomotor symptoms: hot flashes and night sweats, the classic and most common complaint.
• Sleep disruption: sometimes from night sweats, sometimes on its own.
• Genitourinary symptoms: vaginal dryness, discomfort with intercourse, and urinary symptoms.
• Mood and cognitive complaints: irritability, low mood, and reports of "brain fog" or word-finding trouble.
• Menstrual irregularity: the defining feature of perimenopause itself.

The piece that most reshapes counseling is duration. In the Study of Women's Health Across the Nation (SWAN), a large multi-ethnic cohort, frequent vasomotor symptoms lasted a median of about 7.4 years across the transition, and persisted a median of about 4.5 years after the final period. That is considerably longer than the "a year or two and it passes" story many people carry into midlife.

Two caveats keep this honest. First, duration varies widely between individuals and between groups; a median is a middle value, not a promise. Second, SWAN is observational, so an association in that kind of data cannot by itself establish that one factor caused another. The practical value here is planning: if hot flashes may last several years, "just wait it out" is a real choice, but it should be an informed one rather than a default based on a timeline that turns out to be too short.

Hormone therapy: what it treats and where it fits#

Stated neutrally, and consistent with The Menopause Society 2022 hormone therapy position statement: hormone therapy is the most effective treatment available for bothersome vasomotor symptoms and for the genitourinary syndrome of menopause, and it also helps prevent the bone loss that follows the drop in estrogen.

That is the benefit side. The important nuance is that "hormone therapy" is not one thing. Its effects and its risks vary by several dimensions at once:

• Type of hormone (estrogen alone versus estrogen plus a progestogen).
• Dose and route (oral pills versus transdermal patches, gels, or sprays, which reach the bloodstream differently).
• Duration of use and the timing of when treatment starts.
• Whether a progestogen is included, which is standard for anyone who still has a uterus, because unopposed estrogen raises the risk of endometrial problems.

Because of that, the honest general statement is not "hormone therapy is safe" or "hormone therapy is dangerous." It is that hormone therapy is effective for specific symptoms, and its risk profile depends on how, when, and in whom it is used. Timing does most of the work here, which is the subject of the next section.

Weighing benefits and risks by timing and individual factors#

The central framing in current guidance is age and time since menopause.

For most people who are under 60 or within 10 years of their final menstrual period, and who do not have contraindications, the benefit-to-risk balance of hormone therapy for treating bothersome symptoms tends to be favorable. Starting more than 10 years out, or after age 60, shifts that balance, because the absolute risks (for example, of blood clots or stroke) are higher in an older person and there is less symptom benefit to offset them. Same medication, different math, driven largely by when it is begun.

Contraindications matter as much as timing. In general terms, systemic hormone therapy is usually avoided or approached with particular caution in people with certain hormone-sensitive cancers, a history of venous thromboembolism (blood clots), active cardiovascular disease, or active liver disease, among others. This is not a complete list, and it has to be individualized against a full history rather than read off a chart.

The takeaway is not a single yes or no. The same person can be a reasonable candidate at 52 and a less clear one at 63, and the decision belongs in a conversation that accounts for symptoms, personal history, and preferences. These points draw on the 2022 position statement cited above.

Nonhormonal options that have evidence#

Plenty of people cannot use hormone therapy, or simply prefer not to. The good news is that "nonhormonal" no longer means "nothing that works." The Menopause Society 2023 nonhormone therapy position statement reviewed the evidence and identified several options with reasonable support for vasomotor symptoms:

• Cognitive behavioral therapy, a structured talking therapy.
• Clinical hypnosis.
• Certain SSRIs and SNRIs, antidepressant-class medications that also reduce hot flashes.
• Gabapentin.
• Fezolinetant, a newer non-hormonal medication developed specifically for vasomotor symptoms.
• Oxybutynin and, more broadly, weight loss, which were also noted.

Just as useful is what the statement did not recommend on current evidence. Many popular remedies, including a range of over-the-counter supplements and herbal products, and paced respiration (slow, deliberate breathing), did not have the evidence to support a recommendation. That does not prove any single product is useless, but it does mean the marketing has run ahead of the data, and it is fair to say so to a patient weighing where to spend time and money.

For someone with a history of hormone-sensitive cancer, or a personal preference to avoid hormones, these options are not a consolation prize. They are the main event, and several have decent evidence behind them.

Genitourinary and vaginal symptoms: a distinct problem with distinct fixes#

One pattern trips people up: hot flashes eventually fade for many, but vaginal and urinary symptoms often do not. They can even worsen over time, because they stem from persistently low estrogen in the vaginal and urinary tissues rather than from the hormonal swings that drive hot flashes.

This cluster has a name, the genitourinary syndrome of menopause, and it includes vaginal dryness, discomfort or pain with intercourse, and urinary symptoms such as urgency or recurrent irritation. The key clinical point, echoed by ACOG, is that it usually does not improve on its own and responds best to targeted treatment.

The options run in a sensible order:

• First line: over-the-counter vaginal moisturizers (used regularly, not just before sex) and lubricants (used at the time of intercourse). These are simple, low-risk, and often enough.
• When more is needed: low-dose vaginal estrogen or other local therapies delivered right to the tissue.

An important distinction: the local, low-dose route acts largely where it is placed and carries a different risk profile than systemic hormone therapy taken for whole-body symptoms. That difference is why someone who is not a candidate for, or does not want, systemic therapy may still reasonably discuss local treatment for genitourinary symptoms. The Menopause Society and ACOG both address this route.

A shared-decision approach and when to see a clinician#

Almost every choice above is preference-sensitive, which is why the sensible frame is shared decision making rather than a fixed protocol. In practice that looks like:

1. Name the target. Which symptom actually bothers you most, and what would "better" look like? Treating hot flashes, sleep, and vaginal dryness are three different jobs.
2. Lay out the options and their evidence and risks, honestly, including the option of doing nothing for now.
3. Fit them to you: your personal and family history, other medications, and your own preferences about hormones, pills, therapy, or watchful waiting.
4. Plan to revisit. Needs change. A plan that fits at 51 may need adjusting at 55, and hormone therapy in particular is not a set-and-forget decision.

Reasonable prompts to seek individualized care include: symptoms affecting your sleep, mood, or daily life; wanting to know whether hormone therapy is a sensible option for you specifically; and any bleeding pattern that warrants evaluation (for example, bleeding after menopause, which should always be checked).

This piece is educational and general.

Getting through the transition well#

If you are in the thick of this: the transition is normal, the symptoms are real, and the timeline is often longer than the folklore suggests, so it is worth having an actual plan. Sort your symptoms by what bothers you most. For hot flashes, hormone therapy is the most effective option and tends to be reasonable for people under 60 or within a decade of their final period without contraindications, while cognitive behavioral therapy, certain SSRIs and SNRIs, gabapentin, and fezolinetant are evidence-backed alternatives. For vaginal and urinary symptoms, start with moisturizers and lubricants and ask about low-dose local therapy if needed, since those symptoms rarely resolve on their own. Then bring your history and your preferences to a clinician and decide together, knowing you can revisit the plan as things change.